Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/05/2026 07:26 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [03/03/2026 07:15 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [02/23/2026 07:18 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [02/23/2026 06:55 PST] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [02/20/2026 07:15 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [02/18/2026 07:08 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [02/17/2026 07:52 PST] IONS, Expected to Trade Lower After Bearish Insider Trading
• [02/13/2026 15:34 PST] Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Down By 100% ($84.35) From $84.35 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/12/2026 07:58 PST] IONS Expected to Trade Down After Bearish Patterns Develop
• [02/03/2026 10:49 PST] Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Up By 100% ($79.44) From $79.44 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/03/2026 07:19 PST] IONS, Expected to Trade Lower After Bearish Insider Trading
• [01/29/2026 10:29 PST] Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Up By 100% ($77.53) From $77.53 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [01/22/2026 07:18 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [01/21/2026 07:15 PST] IONS, Expected to Trade Lower After Bearish Insider Trading
• [01/21/2026 07:10 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [01/08/2026 07:25 PST] IONS Expected to Trade Up After Bullish Patterns Develop
• [01/07/2026 07:23 PST] IONS, Expected to Trade Lower After Bearish Insider Trading